Literature DB >> 15239083

Characterization of mutations in ATP8B1 associated with hereditary cholestasis.

Leo W J Klomp1, Julie C Vargas, Saskia W C van Mil, Ludmila Pawlikowska, Sandra S Strautnieks, Michiel J T van Eijk, Jenneke A Juijn, Carlos Pabón-Peña, Lauren B Smith, Joseph A DeYoung, Jane A Byrne, Justijn Gombert, Gerda van der Brugge, Ruud Berger, Irena Jankowska, Joanna Pawlowska, Erica Villa, A S Knisely, Richard J Thompson, Nelson B Freimer, Roderick H J Houwen, Laura N Bull.   

Abstract

Progressive familial intrahepatic cholestasis (PFIC) and benign recurrent intrahepatic cholestasis (BRIC) are clinically distinct hereditary disorders. PFIC patients suffer from chronic cholestasis and develop liver fibrosis. BRIC patients experience intermittent attacks of cholestasis that resolve spontaneously. Mutations in ATP8B1 (previously FIC1) may result in PFIC or BRIC. We report the genomic organization of ATP8B1 and mutation analyses of 180 families with PFIC or BRIC that identified 54 distinct disease mutations, including 10 mutations predicted to disrupt splicing, 6 nonsense mutations, 11 small insertion or deletion mutations predicted to induce frameshifts, 1 large genomic deletion, 2 small inframe deletions, and 24 missense mutations. Most mutations are rare, occurring in 1-3 families, or are limited to specific populations. Many patients are compound heterozygous for 2 mutations. Mutation type or location correlates overall with clinical severity: missense mutations are more common in BRIC (58% vs. 38% in PFIC), while nonsense, frameshifting, and large deletion mutations are more common in PFIC (41% vs. 16% in BRIC). Some mutations, however, lead to a wide range of phenotypes, from PFIC to BRIC or even no clinical disease. ATP8B1 mutations were detected in 30% and 41%, respectively, of the PFIC and BRIC patients screened.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15239083     DOI: 10.1002/hep.20285

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  75 in total

1.  Differences in presentation and progression between severe FIC1 and BSEP deficiencies.

Authors:  Ludmila Pawlikowska; Sandra Strautnieks; Irena Jankowska; Piotr Czubkowski; Karan Emerick; Anthony Antoniou; Catherine Wanty; Bjorn Fischler; Emmanuel Jacquemin; Sami Wali; Samra Blanchard; Inge-Merete Nielsen; Billy Bourke; Shirley McQuaid; Florence Lacaille; Jane A Byrne; Albertien M van Eerde; Kaija-Leena Kolho; Leo Klomp; Roderick Houwen; Peter Bacchetti; Steven Lobritto; Vera Hupertz; Patricia McClean; Giorgina Mieli-Vergani; Benjamin Shneider; Antal Nemeth; Etienne Sokal; Nelson B Freimer; A S Knisely; Philip Rosenthal; Peter F Whitington; Joanna Pawlowska; Richard J Thompson; Laura N Bull
Journal:  J Hepatol       Date:  2010-04-13       Impact factor: 25.083

2.  Morphologic findings in progressive familial intrahepatic cholestasis 2 (PFIC2): correlation with genetic and immunohistochemical studies.

Authors:  Kimberley Evason; Kevin E Bove; Milton J Finegold; A S Knisely; Sue Rhee; Philip Rosenthal; Alexander G Miethke; Saul J Karpen; Linda D Ferrell; Grace E Kim
Journal:  Am J Surg Pathol       Date:  2011-05       Impact factor: 6.394

3.  The membrane protein ATPase class I type 8B member 1 signals through protein kinase C zeta to activate the farnesoid X receptor.

Authors:  Tamara Frankenberg; Tamir Miloh; Frank Y Chen; Meena Ananthanarayanan; An-Qiang Sun; Natarajan Balasubramaniyan; Irwin Arias; Kenneth D R Setchell; Frederick J Suchy; Benjamin L Shneider
Journal:  Hepatology       Date:  2008-12       Impact factor: 17.425

4.  Clinical utility gene card for: progressive familial intrahepatic cholestasis type 1.

Authors:  Emmanuel Gonzales; Anne Spraul; Emmanuel Jacquemin
Journal:  Eur J Hum Genet       Date:  2013-08-28       Impact factor: 4.246

5.  Missense mutation in the ATPase, aminophospholipid transporter protein ATP8A2 is associated with cerebellar atrophy and quadrupedal locomotion.

Authors:  Onur Emre Onat; Suleyman Gulsuner; Kaya Bilguvar; Ayse Nazli Basak; Haluk Topaloglu; Meliha Tan; Uner Tan; Murat Gunel; Tayfun Ozcelik
Journal:  Eur J Hum Genet       Date:  2012-08-15       Impact factor: 4.246

Review 6.  Liver transplantation and the management of progressive familial intrahepatic cholestasis in children.

Authors:  Ashley Mehl; Humberto Bohorquez; Maria-Stella Serrano; Gretchen Galliano; Trevor W Reichman
Journal:  World J Transplant       Date:  2016-06-24

7.  Phospholipid Flippase ATP10A Translocates Phosphatidylcholine and Is Involved in Plasma Membrane Dynamics.

Authors:  Tomoki Naito; Hiroyuki Takatsu; Rie Miyano; Naoto Takada; Kazuhisa Nakayama; Hye-Won Shin
Journal:  J Biol Chem       Date:  2015-05-06       Impact factor: 5.157

8.  Biochemical characterization of P4-ATPase mutations identified in patients with progressive familial intrahepatic cholestasis.

Authors:  Alex Stone; Christopher Chau; Christian Eaton; Emily Foran; Mridu Kapur; Edward Prevatt; Nathan Belkin; David Kerr; Torvald Kohlin; Patrick Williamson
Journal:  J Biol Chem       Date:  2012-10-11       Impact factor: 5.157

9.  P-type ATPase TAT-2 negatively regulates monomethyl branched-chain fatty acid mediated function in post-embryonic growth and development in C. elegans.

Authors:  Emylie Seamen; Jennifer M Blanchette; Min Han
Journal:  PLoS Genet       Date:  2009-08-07       Impact factor: 5.917

10.  Strain background modifies phenotypes in the ATP8B1-deficient mouse.

Authors:  Sohela Shah; Ukina R Sanford; Julie C Vargas; Hongmei Xu; Annamiek Groen; Coen C Paulusma; James P Grenert; Ludmila Pawlikowska; Saunak Sen; Ronald P J Oude Elferink; Laura N Bull
Journal:  PLoS One       Date:  2010-02-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.